Some health officials, including Peter Marx, who administered the vaccine to the Food and Drug Administration, support the expansion of people who will receive an additional booster in the first week of April, and argue that the vaccination campaign should start much earlier. People who are knowledgeable about this issue said.
While cases in the United States are still declining, the Biden administration has been closely monitoring Covid’s recent peak in several European countries – where BA.2 is prevalent – and noted that the previous increase here was preceded by growth. The subvariant, which is a more infectious version of Omicron, accounts for about 35 percent of all Covid cases in the US so far. Data from the Centers for Disease Control and Prevention showHowever it is already the majority strain in the New England region.
Administration health officials also reviewed recent data showing that the effectiveness of vaccines is declining. The White House declined to comment.
While there is broad agreement that the fourth shot will eventually be justified, other officials are careful to avoid April 6 meeting FDA Vaccine Advisory Committee.
At this meeting, the agency’s external advisers will discuss the frameworks of who and when should receive boost shots. The FDA has traditionally consulted committee members before making a major decision about a vaccine, and risks angering influential health experts if the agency moves forward without their involvement.
Some health officials are also unsure whether older Americans need a booster. There is no definitive sign that an increase in European cases will lead to an increase in infections in the US. And recent data reviewed by the administration show that although vaccine protection against infection is significantly eroded within a few months, these vaccines still remain largely protective against the risk of serious illness and death. Senior health officials are awaiting more final data from the CDC and Israel to determine the effectiveness of the fourth strike on different groups and populations, according to one expert on the subject.
“The clear encouraging news is that despite the increase in cases, they do not see any increase. [intensive care unit] “Admission,” said Anthony Fauche, chief medical adviser to President Joe Biden, in response to remarks by US officials from European counterparts. “While they see an increase in hospitalization, they think this is due in part to the lack of outstanding people who are allowed to covidate compared to Covid.”
Biden’s top officials have repeatedly stressed that their primary goal for pandemic management is to get people out of the hospital – not to prevent infections. But there is still no consensus in the administration on how much the effectiveness of vaccines against hospitalization should be reduced until another booster is guaranteed.
Further complicating the debate are health officials’ fears about vaccine equality – specifically that authorizing a second booster would only open the door to demographics for people over the age of 65, which further deters whites, even though they are black Americans and non-Latinos. .
Internal discussions came just days after Pfizer and its partner BioNTech formally requested authorization for people over the age of 65 to enable a second amplifier. Moderna also made a similar statement, though it asked the FDA to clean up its amplifier for all adults. On Wednesday, the company said it would file an emergency use authorization request to distribute the vaccine to children under 6 years of age.
These companies did their job based on Israeli data, which indicates that additional firing can strengthen people’s protection from covidium. Pfizer CEO Albert Burla repeatedly pushed the administration to recommend an extra shot, calling it a “necessary” move.
“The protection you get from a third party is good enough, in fact it’s pretty good for hospitalization and death,” he told Face the Nation last week. “It’s not very good for infections, but it does not last long.”
Since then the FDA and the CDC have been in close contact about the companies’s booster applications, said one person who is aware of the issue. The White House, meanwhile, said any decision by the Department of Health should be communicated to the public clearly and conclusively.
An FDA spokesman declined to comment on the internal discussions, but said the agency was “considering requests as quickly as possible, using our thorough and science-based approach.”
The Biden administration wants to avoid a repeat of last year ‘s dirty debate in the first round of amplifiers, dominated by clashes inside and outside the government over whether another shot was needed for the general public – especially as other countries struggled to defend the former. Doses.
The CDC ultimately recommends an enhancer for certain demographics that are considered high-risk, including for people over the age of 65 and other adults who are at risk for exposure to Covid in the workplace. But this compromise has led to confusion and criticism of the administration’s messages. Although the CDC opened its powers to all adults months later, many health officials have accused this episode of stifling the enthusiasm of boosters.
About two-thirds of people over the age of 65 have received an amp, According to CDC data. But less than half of adults have received extra blows.
This time, officials stressed the need to get involved with all the various health agencies about any plans for the second amplifier before it goes public, said one person familiar with the matter.
Internal discussions also took place amid controversy over funding for the Covid response in Congress, where lawmakers have not yet approved the billions of dollars the administration says are needed to purchase more vaccines, treatments and tests.
The administration has enough vaccines at its disposal to supply second boosters to all Americans over the age of 65, officials say. But there are not enough stocks to cover the entire adult population, leading to warnings that the nation could remain on the chart at the end of this year.
The government should begin negotiations on new delivery deals with Pfizer and Moderna in early April to ensure the doses are delivered by the fall, said one official – a process that could not begin until Congress receives more funding.
Sarah Overmohle contributed to this report.
The Biden administration has been reviewing the reinforcing recommendation for weeks
Source link The Biden administration has been reviewing the reinforcing recommendation for weeks